{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:53:18Z","timestamp":1787316798757,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.euf.2024.05.018","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T15:31:07Z","timestamp":1717255867000},"page":"219-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0665-5210","authenticated-orcid":false,"given":"Elizabeth","family":"Nally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Fairhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Baines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cheney-Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Jackson-Spence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.05.018_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2024.05.018_b0010","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2024.05.018_b0015","doi-asserted-by":"crossref","unstructured":"Powles T, Bellmunt J, Comperat E, et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. In press. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.001","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"10.1016\/j.euf.2024.05.018_b0020","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signalling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.euf.2024.05.018_b0025","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/cam4.432","article-title":"HER2 as a target in invasive urothelial carcinoma","volume":"4","author":"Bellmunt","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.euf.2024.05.018_b0030","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.euf.2024.05.018_b0035","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.05.018_b0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2024.05.018_b0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance Lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2-positive metastatic bladder cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.euf.2024.05.018_b0050","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.2024.42.4_suppl.538","article-title":"HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: associations and clinical outcomes for advanced bladder cancer","volume":"42","author":"Aggen","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.05.018_b0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","article-title":"Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2024.05.018_b0060","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. Press release. April 5, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2"},{"key":"10.1016\/j.euf.2024.05.018_b0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.05.018_b0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"15 Suppl","key":"10.1016\/j.euf.2024.05.018_b0075","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1200\/JCO.2021.39.15_suppl.4584","article-title":"An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009)","volume":"39","author":"Sheng","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.euf.2024.05.018_b0080","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euf.2024.05.018_b0085","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1200\/JCO.2022.40.16_suppl.4518","volume":"40","author":"Sheng","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euf.2024.05.018_b0090","article-title":"Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001)","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T08:02:04Z","timestamp":1744531324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456924000816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405456924000816"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.05.018","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier B.V. on behalf of European Association of Urology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}